EP1904088A4 - Compositions and methods for the treatment of cancer - Google Patents

Compositions and methods for the treatment of cancer

Info

Publication number
EP1904088A4
EP1904088A4 EP06784482A EP06784482A EP1904088A4 EP 1904088 A4 EP1904088 A4 EP 1904088A4 EP 06784482 A EP06784482 A EP 06784482A EP 06784482 A EP06784482 A EP 06784482A EP 1904088 A4 EP1904088 A4 EP 1904088A4
Authority
EP
European Patent Office
Prior art keywords
cancer
compositions
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06784482A
Other languages
German (de)
French (fr)
Other versions
EP1904088A2 (en
Inventor
Andrea Alan D D
Toshiyasu Taniguchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of EP1904088A2 publication Critical patent/EP1904088A2/en
Publication of EP1904088A4 publication Critical patent/EP1904088A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4703Regulators; Modulating activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/10Screening for compounds of potential therapeutic value involving cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
EP06784482A 2005-05-24 2006-05-24 Compositions and methods for the treatment of cancer Withdrawn EP1904088A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68413605P 2005-05-24 2005-05-24
PCT/US2006/020390 WO2006127978A2 (en) 2005-05-24 2006-05-24 Compositions and methods for the treatment of cancer

Publications (2)

Publication Number Publication Date
EP1904088A2 EP1904088A2 (en) 2008-04-02
EP1904088A4 true EP1904088A4 (en) 2010-03-31

Family

ID=37452873

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06784482A Withdrawn EP1904088A4 (en) 2005-05-24 2006-05-24 Compositions and methods for the treatment of cancer

Country Status (5)

Country Link
EP (1) EP1904088A4 (en)
JP (1) JP2008545965A (en)
AU (1) AU2006249807A1 (en)
CA (1) CA2609751A1 (en)
WO (1) WO2006127978A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007325900A1 (en) * 2006-10-20 2008-06-05 Dnar, Inc. DNA damage repair inhibitors and methods for treating cancer
JP2010521670A (en) * 2007-03-12 2010-06-24 ダナ ファーバー キャンサー インスティテュート,インコーポレイテッド Use of FANCI and drugs that modulate FANCI in the prognosis, in diagnosis, and in the treatment of cancer
WO2012009475A1 (en) * 2010-07-14 2012-01-19 Oregon Health & Science University Methods of treating cancer with inhibition of lysine-specific demethylase 1
WO2015077753A1 (en) * 2013-11-25 2015-05-28 The University Of Toledo Inhibitors of ercc1-xpf and methods of using the same
AU2016250616B2 (en) * 2015-04-22 2021-01-21 Syn-Nat Products Enterprise LLC Co-crystal composition and its pharmaceutical use
MA45408A (en) 2016-06-17 2019-04-24 Magenta Therapeutics Inc COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005081783A2 (en) * 2004-01-30 2005-09-09 Dana Farber Cancer Institute Method for determination and quantification of radiation or genotoxin exposure

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030093819A1 (en) * 2000-11-03 2003-05-15 D'andrea Alan D. Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof
US20030188326A1 (en) * 2000-11-03 2003-10-02 Dana Farber Cancer Institute Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005081783A2 (en) * 2004-01-30 2005-09-09 Dana Farber Cancer Institute Method for determination and quantification of radiation or genotoxin exposure

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BAGBY GROVER C ET AL: "Cisplatin and the sensitive cell.", NATURE MEDICINE MAY 2003, vol. 9, no. 5, May 2003 (2003-05-01), pages 513 - 514, XP002550337, ISSN: 1078-8956 *
CHIRNOMAS DEBORAH ET AL: "Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway", MOLECULAR CANCER THERAPEUTICS, vol. 5, no. 4, April 2006 (2006-04-01), pages 952 - 961, XP002550338, ISSN: 1535-7163 *

Also Published As

Publication number Publication date
CA2609751A1 (en) 2006-11-30
AU2006249807A1 (en) 2006-11-30
JP2008545965A (en) 2008-12-18
WO2006127978A2 (en) 2006-11-30
WO2006127978A3 (en) 2009-04-30
EP1904088A2 (en) 2008-04-02

Similar Documents

Publication Publication Date Title
EP2125855A4 (en) Methods and compositions for the treatment of cancer or other diseases
ZA200800907B (en) Treatment of cancer
ZA200904492B (en) Compositions and methods for the treatment of infections and tumors
PL1765391T3 (en) Bacterial compositions for the treatment of cancer
EP1928453A4 (en) Methods and compositions for the preventioin and treatment of kidney disease
EP2049151A4 (en) Methods and compositions for the treatment of cancer
WO2007081751A9 (en) Compositions and methods for the treatment of cancer
IL188430A0 (en) Treatment of tumors
ZA200708575B (en) Methods and compositions for treating or preventing cancer
IL176919A0 (en) Methods and compositions for treating cancer
IL196843A0 (en) Compositions and methods for the treatment of radiation proctosigmoitis
ZA200800452B (en) Methods and compositions for the prevention and treatment of kidney disease
EP1812596A4 (en) Treatment of cancer and compositions
HK1164767A1 (en) Compounds and methods for the treatment of cancer
EP1855662A4 (en) Methods and compositions for treating cancer
ZA200708819B (en) Methods and compositions for the prevention and treatment of kidney disease
IL187405A0 (en) Methods and compositions for the treatment of pain
EP2150270A4 (en) Methods and compositions for the treatment of cancer
AU2006251167A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
AU2006251169A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
GB0517387D0 (en) Combinations for the treatment of cancer
EP1904088A4 (en) Compositions and methods for the treatment of cancer
IL187792A0 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of cancer
EP1797430A4 (en) Methods and compositions for the diagnosis and treatment of cancer
IL226363A0 (en) Compounds and methods for the treatment of cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20071221

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

DAX Request for extension of the european patent (deleted)
R17D Deferred search report published (corrected)

Effective date: 20090430

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DANA FARBER CANCER INSTITUTE, INC.

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/00 20060101ALI20090504BHEP

Ipc: A61K 38/00 20060101ALI20090504BHEP

Ipc: G01N 33/53 20060101AFI20090504BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20100301

17Q First examination report despatched

Effective date: 20100616

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DANA-FARBER CANCER INSTITUTE, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20121201